Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 72
Faster-acting insulin aspart provides superior glucose
control vs Novo RapidⓇ in onset 1 trial
Creating a new formulation that satisfies
an unmet medical need
Faster-acting insulin aspart is an innovative formulation
of insulin aspart:
HbA1c reduction in onset 1 trial after 26 weeks
HbA1c
reduction (%)
-
Faster aspart (pm)
-
Faster aspart (mt)
NovoRapidⓇ (mt)
•
Vitamin B3 (nicotinamide) ¹ added to increase early
absorption
0.0
-0.1
Naturally occurring amino acid (arginine) ¹ added to obtain
stability
-0.2
-0.3
Faster-acting insulin aspart is intended to address unmet
medical need:
-0.3*
-0.4
.
•
Faster absorption mimics physiological insulin action profile
A better profile for pump and future closed loop systems
-0.5
-0.6
-0.7
T
0 2
4 6
8
10 12 14 16 18 20 22 24 26
Time (weeks)
*p<0.05; pm: post-meal; mt: meal time
Source: Novo Nordisk on file (NN1218-3852)
1 Concentration often below recommended dietary daily intake
changing
diabetes
novo nordiskView entire presentation